Elsevier

Virology

Volume 259, Issue 2, 5 July 1999, Pages 256-261
Virology

Rapid Communication
Augmentation of Human Influenza A Virus-Specific Cytotoxic T Lymphocyte Memory by Influenza Vaccine and Adjuvanted Carriers (ISCOMS)

https://doi.org/10.1006/viro.1999.9765Get rights and content
Under an Elsevier user license
open archive

Abstract

There is a need to improve the ability of subunit vaccines to induce CD8+ CTL responses in humans, especially for vaccines used to prevent illness by organisms that undergo antigenic variation at their major neutralizing antibody sites, e.g., influenza A viruses and human immunodeficiency virus. Murine models have demonstrated the protective role of cross-reactive CTL against influenza A virus antigenic drift. We tested the ability of an adjuvanted carrier (Iscomatrix) to help human antigen-presenting cells present formalin-killed influenza vaccine to human CD8+ CTL clones in vitro and in vaccinated humans. The results of a randomized, double-blind, controlled clinical study demonstrate that a single dose of a vaccine formulated into Iscom particles increased influenza A virus-specific CTL memory in 50–60% of recipients, compared to 5% of the recipients of the standard influenza vaccine.

Cited by (0)

1

To whom correspondence and reprint requests should be addressed. Fax: (508) 856-4890. E-mail: [email protected].

2

Current address: Intellivax International Inc., 5757 Cavendish Boulevard, Cote St. Luc, Quebec H4W 2WB, Canada.